Tandem t:X2 Insulin Pump Now Compatible with Lyumjev in EU

Tandem Diabetes Care has announced that its t:X2 insulin pump, equipped with Control-IQ technology, is now compatible with Eli Lilly’s ultra-rapid acting insulin, Lyumjev, in the European Union (EU).

This integration provides people with diabetes more flexibility in managing their condition, as Lyumjev’s fast response time is highly valued.

Clinical Study Confirms Positive Results

Jordan Pinsker, MD, Chief Medical Officer at Tandem, highlighted the positive results from a clinical study showcasing improved quality of life and satisfaction when using Lyumjev with Control-IQ.

“High satisfaction and quality of life benefits were recently shown in a clinical study using Lyumjev with Control-IQ technology,” says Dr. Pinkser. “Ultra-rapid acting insulin is a popular choice for people living with diabetes due to its fast response time. We are proud to be able to offer Lyumjev compatibility with our t:slim X2 insulin pump as part of an AID system in the EU, providing more flexibility for our customers in these countries.”

Expanding Compatibility Across Regions

Originally approved for EU pump use in 2020, Lyumjev compatibility with individual pumps requires rigorous testing.

Tandem’s partnership with Eli Lilly has secured this option for t:X2 insulin pump users in Europe, expanding diabetes management options.

Future Plans for Wider Compatibility

Tandem and Lilly are working to achieve Lyumjev compatibility with the t:X2 insulin pump in other regions, as well as the Tandem Mobi pump.

This compatibility is expected to improve diabetes management for many users across Europe, offering quicker, more responsive insulin delivery.